Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical hydrocortisone to prevent capecitabine-related hand-foot syndrome in adjuvant colorectal cancer chemotherapy (T-CRACC)
jRCTs031220002Phase 2Recruiting
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydrocortisone in colorectal cancer (CRC) and Erythrodysesthesia syndrome (PPE). Primary endpoint: Incidence of grade ≥2 hand-foot syndrome at completion of adjuvant chemotherapy. Started Apr 2022; status: recruiting.
02
Drugs
hydrocortisone
03
Conditions
colorectal cancer (CRC)Erythrodysesthesia syndrome (PPE)
Beyond the preview
Go deeper on jRCTs031220002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220002.